Skip to main content
Top
Published in: Tumor Biology 1/2016

01-01-2016 | Research Article

Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma

Authors: Huanxi Xu, Yuqi Yang, Hongmei Zhao, Xuguang Yang, Yu Luo, Yinxiang Ren, Wei Liu, Ning Li

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Deregulation of microRNAs (miRNAs) is essential to tumor development, and serum miRNA profiles have been reported in several cancers. However, the serum miRNA profile in oral squamous cell carcinoma (OSCC) remained unclear. The present study aimed to explore abnormal miRNA profile in sera samples from OSCC patients and the association of miR-483-5p with patient prognosis. Microarray analysis was performed in sera from OSCC patients versus healthy controls. miR-483-5p expression was measured by reverse transcription (RT)-PCR and correlated to clinicopathological characteristics of OSCC patients. The prognostic significance was then evaluated with a Kaplan–Meier curve and log-rank tests, using a Cox proportional hazard model. According to microRNA array, 16 miRNAs were upregulated and 10 were downregulated in OSCC patient sera. miR-483-5p expression was significantly increased in OSCC patients (3.23-fold, p < 0.01), and this was significantly correlated with tumor nodal metastasis (TNM) stage and lymph nodal metastases (p < 0.01, p < 0.01). For predicting OSCC, receiver operating characteristic (ROC)/area under the curve (AUC) analysis confirmed a AUC of 0.85 (sensitivity of 0.853 and specificity of 0.746). OSCC patients with high serum miR-483-5p had lower survival than those with low expression, and multivariate analyses for overall survival revealed that high serum miR-483-5p expression was an independent prognostic factor for OSCC (HR = 2.32, 95 %CI 1.20–4.48). miR-483-5p expression increased in OSCC patient sera, and this may be a novel diagnostic and prognostic biomarker for OSCC.
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed
2.
go back to reference Warnakulasuriya S. Squamous cell carcinoma and precursor lesions: prevention. Periodontol. 2011;2000(57):38–50.CrossRef Warnakulasuriya S. Squamous cell carcinoma and precursor lesions: prevention. Periodontol. 2011;2000(57):38–50.CrossRef
3.
go back to reference Gupta K, Metgud R. Evidences suggesting involvement of viruses in oral squamous cell carcinoma. Patholog Res Int. 2013;2013:642496.PubMedPubMedCentral Gupta K, Metgud R. Evidences suggesting involvement of viruses in oral squamous cell carcinoma. Patholog Res Int. 2013;2013:642496.PubMedPubMedCentral
4.
go back to reference Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol. 2007;43:523–34.CrossRefPubMed Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol. 2007;43:523–34.CrossRefPubMed
7.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRefPubMed
8.
go back to reference Murugan AK, Munirajan AK, Tsuchida N. Ras oncogenes in oral cancer: the past 20 years. Oral Oncol. 2012;48:383–92.CrossRefPubMed Murugan AK, Munirajan AK, Tsuchida N. Ras oncogenes in oral cancer: the past 20 years. Oral Oncol. 2012;48:383–92.CrossRefPubMed
9.
go back to reference Ries J, Vairaktaris E, Kintopp R, Baran C, Neukam FW, et al. Alterations in miRNA expression patterns in whole blood of OSCC patients. In Vivo. 2014;28:851–61.PubMed Ries J, Vairaktaris E, Kintopp R, Baran C, Neukam FW, et al. Alterations in miRNA expression patterns in whole blood of OSCC patients. In Vivo. 2014;28:851–61.PubMed
10.
go back to reference Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31:1429–36.PubMed Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31:1429–36.PubMed
11.
go back to reference Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012;34:219–24.CrossRefPubMed Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012;34:219–24.CrossRefPubMed
12.
go back to reference Qu X, Zhao M, Wu S, Yu W, Xu J, et al. Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol. 2014;31:219.CrossRefPubMed Qu X, Zhao M, Wu S, Yu W, Xu J, et al. Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol. 2014;31:219.CrossRefPubMed
13.
go back to reference Zheng XH, Cui C, Ruan HL, Xue WQ, Zhang SD, et al. Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. Chin J Cancer. 2014;33:330–8.PubMedPubMedCentral Zheng XH, Cui C, Ruan HL, Xue WQ, Zhang SD, et al. Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. Chin J Cancer. 2014;33:330–8.PubMedPubMedCentral
14.
go back to reference Yoon AJ, Wang S, Shen J, Robine N, Philipone E, et al. Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma. Am J Transl Res. 2014;6:580–92.PubMedPubMedCentral Yoon AJ, Wang S, Shen J, Robine N, Philipone E, et al. Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma. Am J Transl Res. 2014;6:580–92.PubMedPubMedCentral
15.
Metadata
Title
Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma
Authors
Huanxi Xu
Yuqi Yang
Hongmei Zhao
Xuguang Yang
Yu Luo
Yinxiang Ren
Wei Liu
Ning Li
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3514-z

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine